Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Cascadian Therapeutics (CASC) Share Price

News articles about Cascadian Therapeutics (NASDAQ:CASC) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cascadian Therapeutics earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.9419204266223 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of CASC stock opened at $10.02 on Friday. The firm has a market cap of $506.61, a price-to-earnings ratio of -7.48 and a beta of 3.79. Cascadian Therapeutics has a 52-week low of $3.18 and a 52-week high of $10.21.

How to Become a New Pot Stock Millionaire

Several research analysts have commented on the stock. ValuEngine raised shares of Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 31st. BidaskClub raised shares of Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Raymond James Financial downgraded shares of Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 31st. Zacks Investment Research downgraded shares of Cascadian Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, Cantor Fitzgerald set a $10.00 price target on shares of Cascadian Therapeutics and gave the company a “hold” rating in a report on Friday, March 9th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. Cascadian Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.17.

TRADEMARK VIOLATION WARNING: This story was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3294803/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-cascadian-therapeutics-casc-share-price.html.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Insider Buying and Selling by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokers Issue Forecasts for Thomson Reuters Corp’s Q1 2018 Earnings
Brokers Issue Forecasts for Thomson Reuters Corp’s Q1 2018 Earnings
Q1 2018 EPS Estimates for Weatherford International  Decreased by Analyst
Q1 2018 EPS Estimates for Weatherford International Decreased by Analyst
Zymeworks  Expected to Post Q1 2018 Earnings of  Per Share
Zymeworks Expected to Post Q1 2018 Earnings of Per Share
PNM Resources  Plans Quarterly Dividend of $0.27
PNM Resources Plans Quarterly Dividend of $0.27
Fortune Brands Home & Security  Reaches New 12-Month High and Low at $55.55
Fortune Brands Home & Security Reaches New 12-Month High and Low at $55.55
Camping World  Sets New 12-Month High and Low at $25.91
Camping World Sets New 12-Month High and Low at $25.91


© 2006-2018 Ticker Report. Google+.